VYNE (VYNE Therapeutics Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by VYNE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-24 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | — | — |
| 2026-07-24 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | — | — |
| 2026-07-24 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | — | — |
| 2026-07-24 | David Domzalski | PRESIDENT AND CEO | F | — | — |
| 2026-07-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | — | — |
| 2026-07-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | — | — |
| 2026-07-02 | David Domzalski | PRESIDENT AND CEO | F | — | — |
| 2026-07-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | — | — |
| 2026-06-02 | David Domzalski | PRESIDENT AND CEO | A | — | — |
| 2026-04-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | — | — |
| 2026-04-02 | David Domzalski | PRESIDENT AND CEO | F | — | — |
| 2026-04-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | — | — |
| 2026-04-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | — | — |
| 2026-01-05 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | — | — |
| 2026-01-05 | David Domzalski | PRESIDENT AND CEO | F | — | — |
| 2026-01-05 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | — | — |
| 2026-01-05 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | — | — |
| 2025-12-15 | Elisabeth Sandoval Little | Director | A | — | — |
| 2025-12-15 | SHARON BARBARI | Director | A | — | — |
| 2025-12-15 | Steven L Basta | Director | A | — | — |
| 2025-12-15 | PATRICK G LEPORE | Director | A | — | — |
| 2025-10-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | — | — |
| 2025-10-02 | David Domzalski | PRESIDENT AND CEO | F | — | — |
| 2025-10-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | — | — |
| 2025-10-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | — | — |
| 2025-07-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | — | — |
| 2025-07-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | — | — |
| 2025-07-02 | David Domzalski | PRESIDENT AND CEO | F | — | — |
| 2025-07-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | — | — |
| 2025-06-03 | David Domzalski | PRESIDENT AND CEO | A | — | — |
| 2025-06-03 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | A | — | — |
| 2025-04-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | — | — |
| 2025-04-02 | David Domzalski | PRESIDENT AND CEO | F | — | — |
| 2025-04-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | — | — |
| 2025-04-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | — | — |
| 2025-01-23 | David Domzalski | PRESIDENT AND CEO | A | — | — |
| 2025-01-23 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-01-23 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2025-01-23 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | A | — | — |
| 2025-01-16 | PATRICK G LEPORE | Director | Buy | — | — |
| 2025-01-02 | David Domzalski | PRESIDENT AND CEO | F | — | — |
| 2025-01-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | — | — |
| 2025-01-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | — | — |
| 2025-01-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | — | — |
| 2024-12-13 | Christine Borowski | Director | A | — | — |
| 2024-12-13 | SHARON BARBARI | Director | A | — | — |
| 2024-12-13 | Anthony D Bruno | Director | A | — | — |
| 2024-12-13 | Elisabeth Sandoval | Director | A | — | — |
| 2024-12-13 | PATRICK G LEPORE | Director | A | — | — |
| 2024-12-13 | Steven L Basta | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | PRESIDENT AND CEO | 6,943 | — |
| — | 10%+ Owner | 5,483 | — |
| — | CHIEF SCIENTIFIC OFFICER | 1,919 | — |
| — | CHIEF LEGAL OFFICER AND GC | 1,918 | — |
| — | CHIEF FINANCIAL OFFICER | 1,498 | — |
| — | Director | 1,029 | — |
| — | Chief Financial Officer | 129 | — |
| — | Chief Commercial Officer | 121 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VYNE quote page; the site-wide leaderboard is on the insider transactions hub.